Alexion Pharmaceuticals, established in 1992, is a renowned global biopharmaceuticals company best known for its Soliris drug used for the treatment of rare disorders such as atypical hemolytic uremic syndrome (aHUS). It has been in the forefront of research into autoimmune diseases. The shares of Alexion are traded on Nasdaq under the symbol Alxn. It has approximately 3000 employees serving patients in 50 countries.
Alexion Pharmaceuticals was founded by Leonard Bell in 1992 at Science Park in New Haven, Connecticut. It became a public limited company in 1996 and was listed in NASDAQ. The first manufacturing facility was set up in New Haven in 1992, the first-in-human clinical trials for eculizumab began in 1996-98 period. The European office was started in 2005.